CGTX — COGNITION THERAPEUTICS INC

—
Nasdaq · Health Care · Biotechnology · CIK 1455365 ·
Last close
$0.63
Market Cap
$59.90M
52W High
$1.81
52W Low
$0.55
ADV30
537,332
Next earnings
—

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -4,411,000 -4,145,000 34,803,000 30,758,000 5,526,000
Jun 2026 0 — -4,220,000 -3,932,000 38,896,000 34,012,000 5,872,000
Mar 2026 0 — -4,838,000 -4,570,000 36,140,000 31,130,000 6,229,000
Dec 2025 0 — -3,672,000 -3,343,000 48,390,000 36,810,000 14,119,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-15,291,000
Investing CF
$-11,000
Financing CF
$6,954,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.19
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-211,294,000
Inventory
—
Receivables
$2,503,000
ST Investments
—
EBIT TTM
$-15,976,000
Pretax Income TTM
$-15,990,000
Interest Exp TTM
$14,000
Analysts
2

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -24,393,000 -23,487,000 48,390,000 14,119,000 34,271,000 -24,588,000
Dec 2024 0 -34,417,000 -33,971,000 30,234,000 11,484,000 18,750,000 -28,474,000
Dec 2023 0 -25,919,000 -25,788,000 35,163,000 10,689,000 24,474,000 -16,018,000
Dec 2022 0 -21,334,000 -21,397,000 50,425,000 10,176,000 40,249,000 -18,533,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-16,775,000
OpCashFlow TTM
—
Assets (Latest)
$38,896,000
Forward EPS
$-0.19

Peers — same industry

TickerNameMarket CapLastDaily %
PMCB PharmaCyte Biotech, Inc. $58.19M $5.42 —
OKYO OKYO Pharma Ltd $57.99M $1.11 —
NMRA Neumora Therapeutics, Inc. $62.85M $0.33 —
VISK Viskase Holdings, Inc. $63.49M $4.43 —
CSBR CHAMPIONS ONCOLOGY, INC. $63.91M $4.59 —

News headlines (Yahoo Finance, 1h cache)

Cognition Therapeutics Announces CTAD Poster Highlighting Screening Efficiencies with p-Tau217 in the Ongoing Phase 2 START Study
2026-11-17 11:00 · Yahoo
What Makes Cognition Therapeutics (CGTX) a New Buy Stock
2026-11-10 19:43 · Yahoo
Cognition Therapeutics Invited to Participate in 2026 Jefferies Global Healthcare Conference
2026-11-09 12:30 · Yahoo
Cognition Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-05 23:25 · Yahoo
Cognition Tx (CGTX) Q3 2026 Earnings Call Transcript
2026-11-05 20:45 · Yahoo
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update
2026-11-05 11:00 · Yahoo
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026
2026-11-02 12:30 · Yahoo
Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies
2026-10-22 10:00 · Yahoo
Cognition Therapeutics Secures US Patent for Zervimesine Through 2045 Ahead of Planned Phase 3 Development
2026-10-13 10:59 · Yahoo
Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
2026-10-13 10:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.